Real-World Survival Outcomes in Non–Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country
JCO Global Oncology · 2024
DOI: 10.1200/go-24-00338 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JCO Global Oncology, 2024. Verfasst von Juan-Manuel Hernandez-Martinez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Medicina Personalizada de la Unidad de Oncología Torácica, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Molecular Targeted Therapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Targeted therapies are indicated for patients with non–small cell lung cancer (NSCLC) and driver tumor mutations. However, real-world studies on the survival benefits of these agents are limited. This study aimed to evaluate the effect of targeted therapies matched to a genomic alteration on the survival of patients with NSCLC. METHODS This retrospective study included 446 patients with advanced NSCLC who underwent next-generation sequencing between 2016 and 2023 at the Instituto Nacional de Cancerología in Mexico. The primary outcomes were progression-free survival (PFS) and overall survival (OS). RESULTS For the entire cohort, the PFS and OS were 10.71 months (95% CI, 9.35 to 12.06) and 47.77 months (95% CI, 29.67 to 65.86). PFS was significantly longer in patients with actionable mutations treated with targeted therapies (19.41 months [95% CI, 14.27 to 24.55]; P < .001) than in patients without actionable mutations (6.4 months [95% CI, 4.4 to 8.4]) or not treated with targeted therapies (6.6 months [95% CI, 5.3 to 7.89]). Similarly, OS was significantly longer in patients with actionable mutations treated with targeted therapies (89.69 months [95% CI, 45.54 to 133.84]; P < .001) than in patients without actionable mutations (17.11 months [95% CI, 8.65 to 25.57]) or not treated with targeted therapies (22.3 months [95% CI, 12.48 to 32.1]). Survival gains were driven by significant improvements in PFS and OS in patients with EGFR and ALK mutations. CONCLUSION This real-world data analysis demonstrated that targeted therapies improve the survival of patients with NSCLC with actionable mutations, which supports a recommendation for widening access to broad-based genomic testing and targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Laboratorio de Medicina Personalizada de la Unidad de Oncología Torácica, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
- Thoracic Oncology Unit, Department of Thoracic Oncology, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
- CONAHCYT-Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
- Direction of Research and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia.
- Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.
- Molecular Oncology and Biology Systems Research Group (FOX-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia.
ORCID-Profile: Juan-Manuel Hernandez-Martinez, Alberto Guijosa, Jenny Turcott, Norma Hernández-Pedro, Enrique Caballé-Perez, Andrés F Cardona, Oscar Arrieta
Zitieren
APA
Hernandez-Martinez, J. M., Guijosa, A., Flores-Estrada, D., Cruz-Rico, G., Turcott, J., Hernández-Pedro, N., Caballé-Perez, E., Cardona, A. F., & Arrieta, O. (2024). Real-World Survival Outcomes in Non–Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country. JCO Global Oncology. https://doi.org/10.1200/go-24-00338
Vancouver
Hernandez-Martinez JM, Guijosa A, Flores-Estrada D, Cruz-Rico G, Turcott J, Hernández-Pedro N, et al. Real-World Survival Outcomes in Non–Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country. JCO Global Oncology. 2024. doi:10.1200/go-24-00338
BibTeX
@article{HernandezMartinez2024,
author = {Hernandez-Martinez, Juan-Manuel and Guijosa, Alberto and Flores-Estrada, Diana and Cruz-Rico, Graciela and Turcott, Jenny and Hernández-Pedro, Norma and Caballé-Perez, Enrique and Cardona, Andrés F and Arrieta, Oscar},
title = {Real-World Survival Outcomes in Non–Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country},
journal = {JCO Global Oncology},
year = {2024},
doi = {10.1200/go-24-00338}
}
EUVIMED